Literature DB >> 26686944

Utility of Exposure-Response Analysis in Regulatory Decision on the Selection of Starting Dose of Pasireotide for Cushing Disease.

Jingyu Yu1, Sang Chung2, Immo Zadezensky2, Ke Hu3, Christelle Darstein4, Jerry Nedelman3, Nitin Mehrotra1.   

Abstract

Entities:  

Keywords:  Clinical Pharmacology (CPH); Clinical Trials (CTR); Endocrinology (END); Pharmacometrics; Regulatory/Scientific Affairs (REG)

Mesh:

Substances:

Year:  2016        PMID: 26686944     DOI: 10.1002/jcph.694

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  2 in total

1.  Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease Patients.

Authors:  Jerry Nedelman; Roland Fisch; Ke Hu; Ines Paule; Jocelyn Zhou
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

Review 2.  Pharmacometrics: The Already-Present Future of Precision Pharmacology.

Authors:  Lorena Cera Bandeira; Leonardo Pinto; Cláudia Martins Carneiro
Journal:  Ther Innov Regul Sci       Date:  2022-08-18       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.